PubMed Health⌕ Search

Biomedical subjects

K Bieroń

Publications and source records attributed to K Bieroń.

25 records · Page 2Linked to original sources
PubMedDate not supplied

[Use of nitrendipine in treating patients with obliterative atherosclerosis of arteries in the lower extremities].

Twenty patients with obliterative atherosclerosis in the lower extremities arteries (Fontaine's stage II) were treated with nitrendipine (Bayotensin) given in the dose of 20 mg daily for 6 weeks. This therapy with nitrendipine produced improvement manifested by the prolongation of the distance of intermittent claudication, shortening of pain duration, increase in blood flow in the ischemic extremity, and increase in pressure index. At the same time, nitrendipine decreased ADP-produced platelet aggregation and activated fibrinolytic system. Clinical trials have shown that nitrendipine is effective in the obliterative atherosclerosis in the lower extremities.

Adult↗
PubMedDate not supplied

[Kallikrein in the treatment of patients with obliterative atherosclerosis of the lower limbs and its mechanism of action].

Kallikrein (Padutin-Depot) was administered to 20 patients with obliterative atherosclerosis of the lower limbs of the II degree (19 patients) and IV degree (1 patient). The drug was given in the daily dose of 40 U i.m. for 28 days. An effect of kallikrein on the distance in intermittent claudication, rate of pain relieve after walking the maximal distance, blood flow in the lower limbs, and on the index of circulating aggregates have been determined. Clinical improvement has been noted after a 4-week therapy with kallikrein. The drug in a single dose of 40 U activates plasma fibrinolytic system for 5 hours and decreases the number of circulating aggregates (2-5 h). The authors explain kallikrein action as the release of endogenous bradykinin, which subsequently releases two epithelial mediators, i.e. PFG1 and EDRF.

Adult↗
PubMedDate not supplied

[Use of prostacyclin in patients with ischemic stroke. A double-blind method II].

Thirty patients with acute ischaemic stroke were allocated randomly into a group treated with prostacyclin and a group receiving placebo. The treatment was started 24 to 72 hours after the onset of stroke. Prostacyclin sodium (Wellcome, U.K. or Chinoin, HPR) or its solvent (glycine buffer) were administered intravenously once daily during 2 weeks in 6-hour infusions. Prostacyclin was infused at rates of 2.5-5.0 ng/kg/min. Statistically significant improvement appeared from the second day on in the prostacyclin group, and only from the eighth day on in the placebo group. However, the final improvement was not statistically different between these groups.

Adult↗
PubMedDate not supplied

Plasma antioxidant potency and serum copper levels in atherosclerosis.

Blood plasma of patients with arteriosclerosis obliterans and diabetes showed a higher antioxidant potency as compared with plasma of healthy volunteers. Serum copper level in those patients was also elevated, but on the contrary to healthy subjects no correlation between serum copper level and plasma antioxidant potency was found. Similar changes were observed in rabbits fed four weeks with atherogenic diet. Administration of vitamin E increased plasma antioxidant potency, however, only in the patients suffering from arteriosclerosis obliterans with high regime of dosage of vitamin E (3 X 200 mg daily p.o.). N-ethylmaldimide-stimulated (malondialdehyde (MDA)) generation by washed platelets was suppressed by addition of homologous plasma to washed platelet preparation. Preincubation of rat aortic tissue with plasma from healthy volunteers resulted in an increase in PGI2-biosynthesis b 75%. We were not able to demonstrate the antioxidant activity of aortic endothelial cell homogenates. We conclude that antioxidant properties of plasma may play an important role in protection of serum lipids against autooxidation. Antioxidant ability of plasma is not exclusively correlated with plasma copper or ceruloplasmin level.

Adult↗
PubMedDate not supplied

[The efficacy of "Ticlid" in treatment of diabetic retinopathy].

PURPOSE: The efficacy of "Ticlid" (ticlopidine) with insulin-dependent patients and early forms of diabetic retinopathy was evaluated. MATERIAL AND METHODS: Examinations were carried out with 52 patients (103 eyes), including 31 women and 21 men, average age--39.9. With 33 patients (65 eyes), ticlopidine was applied twice a day in the dose of 250 mg, the rest, i.e. 19 patients (38 eyes), the control group, received a Rutinoscorbine tablet three times a day. Before the beginning of the treatment and then every three months the following parameters were examined: visual acuity for far and near distances, ophthalmoscopy, fluorescein angiography and colour photography of the fundus. With the group of patients who received ticlopidine, fibrinolytic activity of plasma (ECLT), threshold pro-aggregative concentration for ADP in rich platelet plasma and the factor of platelet aggregates (WAP) were determined. The follow-up time of the patients lasted from 16 to 36 months (average 21.5 months). RESULTS: More frequent although nonsignificant improvement and stabilization of far distance visual acuity was ascertained in the patients receiving ticlopidine. The same group manifested a significantly frequent (p < 0.02) improvement and stabilization of the changes in the fundus. A significant shortening of ECLT (p < 0.01), a complete stopping of II phase aggregation, a significant (p < 0.01) increase in WAP could be observed as well. The above results indicate the favourable influence of ticlopidine on retina vessels in patients with the symptoms of diabetic retinopathy.

Adult↗